speb/financial-data huggingface dataset:
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Investmentsin Associatesat Cost: 2236000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 28104000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 863000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 2133000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 31104000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 33237000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 28104000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -27730000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 2236000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 922000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 29425000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Minority Interest: -75000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Minority Interests: 39000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -40000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Net Debt: 23993000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -54000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Income: -610000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: -610000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: -649000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: -610000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: -610000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 278000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: -649000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Interest Income: -1784000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -118000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 2317000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 374000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -1784000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: 2445000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Net PPE: 34633000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -7959000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 1943000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 20197000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 2685000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 2275000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 3062000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 152000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 8149000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Normalized Income: -158500000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 6607000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Operating Income: 2299000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Operating Revenue: 62193000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 159071682.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 56000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 1217800000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 62000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 9510000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 12590000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 2352000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 9000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 2685100000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 113000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 6800000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Payable: 3823000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Properties: 25918700000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 2469000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 44000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Other Special Charges: 595000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Payables: 12691000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 1379000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Pretax Income: 278000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -127000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -8145000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 6326000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 22228000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 5540000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 78000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 78000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -27730000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -40000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 35000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 45368000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 9000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 186000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 1616000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 3847000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Share Issued: 159281139.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Special Income Charges: -595000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 37000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 53993000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 20197000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -193500000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Tax Provision: 927000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.30
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 116000000.00
JUBLPHARMA.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -2043000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Assets: 111567000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 85097000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Debt: 36768000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 53918000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Total Expenses: 59894000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 57649000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 73943000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 39925000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 196000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 624000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -645000000.00
JUBLPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -645000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 19000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 209457.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Work In Process: 4534000000.00
JUBLPHARMA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 19900000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 36996000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 66448000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 8563000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 9159000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -19972000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 398000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -668000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Amortization: 521000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 521000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 2439000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 322000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 158505987.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Basic EPS: 4.87
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 10139000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 10543000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -8977000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 2499000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 9539000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 9626000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -798000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 519000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 9020000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 908000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 329000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Payable: 232000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 1062000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 2531000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -691000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 158000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -798000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 54339000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 0.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: -274000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 14064000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 24221000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 38761000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 521000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 2470000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 2991000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 18890000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 664000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation: 3298000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 3819000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 3819000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 3298000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 158856621.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Diluted EPS: 4.86
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 771000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 25000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 268000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — EBIT: 4269000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — EBITDA: 8088000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 116000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 9564000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 22000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -4325000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 3267000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 736000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -2000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -2000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 2263000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill: 24639000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 35072000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 9827000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 58384000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Gross Profit: 42227000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense: 2564000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 2564000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income: 261000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 261000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -2437000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 257000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Inventory: 12896000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 88480000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -6079000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 344000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 78000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 0.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 1172000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 879000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 1978000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 31671000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 33649000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 1172000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -759000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 78000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 1001000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 32898000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Minority Interest: -128000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Minority Interests: 44000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -274000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Debt: 24602000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 14000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income: 771000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 771000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 727000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 771000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 771000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 1705000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 727000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Interest Income: -2462000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -21000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -204000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 413000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -2462000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: 2297000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 38412000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -8880000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -617000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 19267000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 5438000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 2327000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 2108000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 235000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 9775000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Normalized Income: 1951900000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 9713000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Operating Income: 5231000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 66448000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 158350737.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 10000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 1632000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 145000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 10433000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 4151000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 8000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 5438000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 154000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 6873000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 5279000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 24348000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 3350000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 87000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Other Special Charges: 1689000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Payables: 14237000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 1085000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Pretax Income: 1705000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -78000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -8977000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 6129000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 24221000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 3819000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 49000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 49000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -759000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -274000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 29000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 45397000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 57000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 97000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 2143000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 4406000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 159281139.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Special Income Charges: -1689000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 85000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 54339000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 19267000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -506100000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Tax Provision: 978000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.30
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 167000000.00
JUBLPHARMA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -2077000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 115485000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 86010000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 36640000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 54211000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Total Expenses: 61217000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 61274000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 76724000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 42384000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 159000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 370000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -1687000000.00
JUBLPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -1687000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Tradeand Other Payables Non Current: 188000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 930402.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Work In Process: 3500000000.00
JUBLPHARMA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 19871000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 8258000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 7950000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Assets Held For Sale Current: 0.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 552000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 2554000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 10769000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 12885000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 59405000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 18574000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 35018000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 523000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 2831000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 3354000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 19468000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 654000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 24800000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 35533000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 42659000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 11615000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 87655000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 552000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentsin Associatesat Cost: 79000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 2031000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 25419000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 27450000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 79000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 1022000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: -135000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 17481000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 42659000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 23872000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 2461000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 2187000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 158396729.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 2190000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 1692000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 59247000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 10733000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 2628000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 8520000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 24085000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 12000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 2116000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 8335000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 159281139.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 59405000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 23872000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 366000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 119244000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 84824000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 30804000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 59270000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 59974000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 84226000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 40506000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 77000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Treasury Shares Number: 884410.00
JUBLPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 15550000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 10432000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 18137000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 158398744.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 6.37
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 5744000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 913000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 913000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 158647799.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 6.36
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 1009000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — EBIT: 1861000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — EBITDA: 2774000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 12393000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 556000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 556000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Minority Interests: 2000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income: 1009000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 1009000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 1007000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 1009000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 1009000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 1007000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -556000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -556000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 2963000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 1154841379.31
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Income: 1961000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 18137000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 92000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 3998000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 1305000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 5744000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 913000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: -189000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: -43158620.69
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 298000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.23
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 16176000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: -189000000.00
JUBLPHARMA.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -189000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — +Operating Expense: 40700000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 10395000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — +Total Revenue: 71921000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 19158000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 10048000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 10048000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 8915000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 8915000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -17876000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -17876000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 398000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 398000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -674000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -674000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Amortization: 627000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 627000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Assets Held For Sale Current: 675000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 675000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 415000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 415000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 158407247.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 158187436.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Basic EPS: 52.99
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 9.71
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 9564000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 9782000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 9782000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -11156000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 2941000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 2941000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 10862000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 10862000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 10986000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 10986000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -796000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 197000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 197000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 10665000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 10665000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Inventory: 785000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -170000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Payable: 553000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -50000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 1118000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 1071000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 158000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Dividend Paid: -796000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 62549000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 62549000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 9000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: -56000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 27258000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 27258000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 23170000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 6261000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Assets: 35772000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 35772000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 556000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 556000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt: 2866000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 2866000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 3422000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 3422000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 21646000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 21646000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 784000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 784000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation: 3686000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 3686000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 3686000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 952000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 3686000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 952000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 158826868.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 158677686.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Diluted EPS: 52.85
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 9.68
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 8394000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1536000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 21000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 21000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 0.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — EBIT: 12209000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — EBIT: 2587000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — EBITDA: 15895000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — EBITDA: 3539000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 248000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — End Cash Position: 10883000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 5000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 5000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -14527000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 2963000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 2963000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -435000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: 17000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -13000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 2132000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill: 25410000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 25410000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 36377000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 36377000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 9589000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 9589000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 69669000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 69669000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Gross Profit: 48751000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 12897000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense: 2403000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 527000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 2403000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 527000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income: 366000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 366000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -2356000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 384000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Inventory: 11292000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 11292000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 86918000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 86918000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: 4877000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 420000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 420000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Investmentsin Associatesat Cost: 75000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Associatesat Cost: 75000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 9000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 49000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 809000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 809000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 2385000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 2385000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 21503000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 21503000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 23888000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 23888000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 49000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -11004000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 75000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 75000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 1191000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 1191000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 31820000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 31820000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Minority Interest: -163000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: -163000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Minority Interests: 31000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 23000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: -47000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Debt: 13507000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 13507000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 1000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income: 8394000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income: 1536000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 8394000000.00